EndoCyclic Therapeutics

EndoCyclic Therapeutics is revolutionizing women’s health with groundbreaking therapeutics and diagnostics for gynecological and cancer disorders. Its proprietary platform technology has produced ENDO-205, the first non-hormonal, disease-modifying ("curative") therapeutic for endometriosis, and ENDO-210, a targeted diagnostic agent for definitive MRI diagnosis. 

Endometriosis affects over 190 million women globally, is the leading cause of female infertility and disability, and imposes more than $100 billion in costs on the U.S. healthcare system. Characterized by the growth of uterine tissue outside the uterus, this condition results in severe pain and fertility issues, with no existing cure and current treatments failing to halt its progression. 

The company's therapeutic approach targets diseased endometriosis tissue and eradicates lesions, aiming to eliminate the need for surgery or long-term medication, which often results in over 50% recurrence within 1-5 years. A short-term treatment course of ENDO-205, lasting up to 3 months, is expected to clear all lesions, liberating women from this debilitating condition. ENDO-210 also serves as a standalone or companion diagnostic to ensure accurate diagnosis and disease elimination.